VeonGen secures FDA alignment on VG801 Phase 3 for Stargardt disease
VeonGen Therapeutics has announced that the US Food and Drug Administration has aligned on the pivotal Phase 3 study design for VG801, its investigational dual-AAV gene therapy targeting Stargardt disease and other ABCA4-associated retinal dystrophies. The agreement, reached at a Regenerative Medicine Advanced Therapy (RMAT) Type B meeting, covers the primary endpoint, study duration, control arm structure, and key aspects of chemistry, manufacturing and controls (CMC), including the use of the existing clinical batch for the pivotal study.
The Munich-headquartered company also released 12-month data from its ongoing first-in-human Phase 1/2 study, which has now dosed 15 patients across three cohorts including both adults and children. Among the 13 patients with measurable baseline best-corrected visual acuity (BCVA), all showed improvement at Month 6 or Month 12. Eleven achieved gains of at least 5 ETDRS letters, seven reached at least 10 letters, and four achieved at least 15 letters. VeonGen reported stable retinal structures and a favourable safety profile to date.
Regulatory milestones
Co-founder and chief executive Caroline Man Xu said the FDA alignment represented "an important de-risking milestone" for the programme, adding that the sustained improvements in both adult and paediatric patients reinforced the company's confidence. VG801 already holds FDA RMAT, Rare Paediatric Disease, and Orphan Drug designations, and has been selected for the FDA's Rare Disease Endpoint Advancement (RDEA) pilot programme, through which VeonGen is advancing its Virtual Reality Visual Test (VRVT) as a novel functional endpoint. Phase 1/2 authorisations have also been granted in Europe and China, supporting a global development strategy.
VG801 uses VeonGen's proprietary vgAAV2 capsid in combination with the company's vgRNA REVeRT mRNA trans-splicing technology, an approach designed to reconstitute a full-length functional ABCA4 gene in retinal photoreceptor cells. Because standard single-AAV vectors cannot accommodate the ABCA4 coding sequence in its entirety, the dual-AAV strategy has been a focus of several groups working in this space, and VeonGen's genotype-agnostic positioning is a key commercial differentiator if the clinical profile holds into pivotal studies.
Market context
Stargardt disease affects approximately one in 8,000 to 10,000 people worldwide and is the most common inherited macular dystrophy, with no approved treatments currently available. That unmet need has drawn both academic programmes and commercial gene therapy developers to the ABCA4 field. The FDA's willingness to progress an RMAT designation and engage substantively on CMC ahead of Phase 3 is a meaningful signal, though the pivotal readout remains some years away. Investors will note that CMC alignment on an existing clinical batch removes a material manufacturing risk, potentially shortening the path to pivotal study start.
The broader inherited retinal disease space has seen mixed fortunes. Spark Therapeutics' Luxturna, approved in 2017 for RPE65-associated retinal dystrophy, demonstrated proof of concept for AAV-based retinal gene therapy but its commercial uptake has been modest relative to early expectations, partly reflecting the rarity of the target population. VeonGen's focus on Stargardt disease addresses a larger patient pool, which may support a more scalable commercial model. Near-term milestones to watch include the pivotal Phase 3 study start date, the RDEA pilot outcome for the VRVT endpoint, and any update on the company's financing position as it moves toward a considerably larger and more expensive programme.